Determination of Advanced Glycation End Products in Serum by Fluorescence Spectroscopy and Competitive ELISA by Münch, Gerald et al.
Eur J Clin Chem Clin Biochem 1997; 35(9):669-677 © 1997 by Walter de Gruyter · Berlin · New York
Determination of Advanced Glycation End Products in Serum by
Fluorescence Spectroscopy and Competitive ELISA1)
Gerald Münch, Regina Keis, Andrea Weßels, Peter Riederer, Udo Bahner, August Heidland, Toshimitsu Niwa,
Horst-Dieter Lemke and Reinhard Schinzel
Physiologische Chemie I, Biozentrum, Am Hubland, Würzburg, Germany
Summary: Recent studies suggest that advanced glycation endproducts play an important role in cardiovascular com-
plications of ageing, diabetes and end-stage renal failure. Since highly elevated levels of advanced glycation endpro-
ducts are present in serum of patients on maintenance haemodialysis, an accurate and rapid assay for their determination
would be useful. This would be particularly valuable for monitoring the removal of advanced glycation endproducts
by novel dialysis membranes, as well as the effect of new drugs for the inhibition of their formation.
Measurement of advanced glycation endproducts in serum was performed by two competitive ELISAs, using a
monoclonal antibody directed against imidazolone, an advanced glycation endproduct formed by the reaction of
arginine with 3-deoxyglucosone, and a polyclonal antibody directed against keyhole limpet haemocyanin-advanced
glycation endproduct, as well as by quantitative fluorescence spectroscopy.
Each of the assays showed significant differences between the controls and the maintenance haemodialysis patients.
Advanced glycation endproduct levels determined by each of the ELISAs correlated with total and protein-bound
fluorescence, but not with each other, suggesting a variable distribution of advanced glycation endproducts on
serum proteins among the maintenance haemodialysis patients.
Introduction
Advanced glycation endproducts are generated by the
non-enzymatic reaction of a sugar ketone or aldehyde
group with the free amino group of proteins or amino
acids. In the first step, a labile Schiff'base is formed,
which subsequently rearranges into the stable Amadori-
product. Finally, advanced glycation endproducts are
formed as a mixture of protein-bound nitrogen and oxy-
gen-containing heterocyclic compounds through a com-
plex cascade of dehydration, condensation, fragmenta-
tion, oxidation and cyclization reactions (1, 2). A variety
of chemical advanced glycation endproduct structures
have been elucidated, some of which are non-fluorescent
like Ne-(carboxymethyl)lysine, pyralline or imidazol-
one, or fluorescent like pentosidine or the crosslinks
(3,4).
A mild rise of advanced glycation levels is associated
with normal ageing in long-lived tissue proteins, e. g. in
collagen, where it has been shown that the glycoxidation
products, e.g. NE-(carboxymethyl)lysine and pentosi-
dine, as well as glycation-related collagen-linked fluo-
rescence increase with age (5).
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A more striking rise of advanced glycation endproducts
is observed in diabetic patients as a result of sustained
hyperglycaemia. In uraemia, the rise of advanced glyca-
tion endproducts is even more marked than in diabetics
and is associated with a variety of tissue disorders in-
cluding vascular damage, dyslipidaemia, and ß2-micro-
globulin amyloidosis. Whereas in diabetes, higher ad-
vanced glycation endproduct levels are caused by an ele-
vated level of plasma glucose, the major mechanism for
increased advanced glycation endproduct levels in end-
stage renal failure might be the impaired renal excretion
and the insufficient clearance by dialysis membranes
(6-9).
Advanced glycation endproduct-mediated crosslinks
generated in proteins contribute to the age-related de-
cline in the function of cells and tissues in the normal
ageing process, in Alzheimer's disease, in diabetes and
maintenance haemodialysis (10—12). Recent progress in
the understanding of this process has affirmed the hy-
pothesis that advanced glycation endproducts play an
important role in the evolution of accelerated vascular
complications in diabetes, end-stage renal failure and re-
nal replacement therapy with maintenance haemodialy-
sis. Advanced glycation endproducts have been iden-
tified in a variety of lipoprotein and lipid constituents of
the vascular wall, leading to micro- and macroangiopa-
thy, the so called "late diabetic complications". In detail,
atherosclerosis, cataract and diabetic retinopathy, ne-
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phropathy and polyneuropathy may be caused by ad-
vanced glycation endproducts (13 — 15). Thus it is be-
lieved that the use of dialysis procedures and mem-
branes that lower the level of advanced glycation end-
products may be a promising approach to lowering the
risk of cardiovascular complications for patients.
So far, the advanced glycation endproduct level in serum
or plasma has been measured by HPLC with fluores-
cence detection of a single substance such as pentosidine
or, in most studies, by competitive ELISA with poly- or
monoclonal antibodies raised against synthetic advanced
glycation endproducts. In this study we compare ad-
vanced glycation endproduct levels determined by total
and protein-bound fluorescence with those determined
by competitive ELISAs using two different antibodies.
Methods
Serum samples
Serum was obtained from 19 control subjects (age: 69.7 ± 7.8
years) and 153 patients on long term maintenance haemodialysis
therapy (age: 62.7 ± 13.1 years, 5.1 ± 4.8 years on dialysis). The
intervals between dialysis sessions were 48-72 hours. Serum was
stored frozen at -20 °C.
Quantitative fluorescence spectroscopy
Serum was diluted 500 fold with phosphate-buffered saline. Due
to the viscosity of the serum, 20 μΐ (sensitivity limit) were used
and diluted into 10ml. After filtration through Millex-GV filters
(0.22 urn Millipore), fluorescence spectra (corrected for back-
ground) were recorded in triplicate on a Fluoromax spectrometer
(Spex instruments) at room temperature. Emission and excitation
slid widths were set to one nm. To compare different sera, the
excitation wavelength was set to 370 nm, and the signal intensity
was measured at the emission maximum of 445 nm and expressed
in arbitrary units (2). The inter-assay coefficient of variation was
8.9% (triplicates on the same day, η = 35). Day to day variation
(5 days) was 10.5% (n = 35).
Competitive ELISA
Polyclonal keyhole limpet haemocyanin-advanced glycation end-
product antibody
The polyclonal rabbit antibody was raised against advanced glyca-
tion endproduct-modified keyhole limpet haemocyanin, which had
been prepared by incubating the protein with 1 mol/1 glucose for 3
months at 50 °C . The ELISA was performed in triplicate in a
modification of the assay employed by Papanastasiou et al. (16).
Briefly, 96-well microtitre plates were coated overnight with artifi-
cial bovine serum albumin-advanced glycation endproduct (3 mg/1
in 0.1 mol/1 sodium carbonate buffer, pH 9.5). Wells were blocked
for one hour with phosphate-buffered saline containing 60 g/1 bo-
vine serum albumin, 10 ml/1 foetal calf serum and 0.5 g/1 Tween
20. Serum samples, diluted 1:4 in assay buffer (phosphate-buf-
fered saline + 0.5 mol/1 KC1, 0.5 g/1 Tween 20 and 60 g/1 bovine
serum albumin), were added to antiserum (1 : 400). After incuba-
tion for two hours and three washing steps, alkaline phosphate-
linked anti rabbit IgG (1 :2000) in wash buffer (phosphate-buf-
fered saline with 0.5 g/1 Tween 20) was added, incubated for one
hour and washed again. Colour was developed with/Miitrophenyl-
phosphate diluted in glycine buffer (pH 10.4); absorbance at 405
nm was read in a microplate reader. The inter-assay coefficient of
variation was 6.60% (triplicates on the same day, n = 172). Day
to day variation (3 days) was 8.75% (n = 19).
Monoclonal imidazolone antibody
The anti-imidazolone antibody was raised by immunizing mice
with advanced glycation endproduct-modified keyhole limpet
haemocyanin produced by incubating the protein with glucose. One
of the two resulting positive clones specifically recognized imida-
zolone (3). The 96-well microtitre plate was coated overnight with
synthetic bovine serum albumin-advanced glycation endproduct
(0.4 mg/1 in 0.1 mol/1 sodium carbonate buffer, pH 9.5). For one
hour the wells were blocked with blocking buffer (phosphate-buf-
fered saline + 60 g/1 bovine serum albumin + 0.5 g/1 Tween 20).
After one washing step, serum samples, diluted 1 : 4 in wash buffer
(phosphate-buffered saline + 0.5 g/1 Tween 20), were added to the
antiserum (dilution: 1 :2000) and incubated for two hours. They
were washed six times, then peroxidase-linked anti mouse IgG
(1 : 10000) in wash buffer was added. After incubation for one
hour and six washing steps, colour was developed with 2,2'-azino-
bis(3-ethylbenzthiazoline-6-sulphonic acid) and H2O2 in substrate
buffer (NaCH3COO + NaH2PO4, pH 4.2). The absorbance was
also read in a microplate reader at 405 nm. The inter-assay coeffi-
cient of variation was 5.54% (triplicates on the same day, n = 79).
Day to day variation (3 days) was 4.35% (n = 10). All steps in both
ELISAs were performed at room temperature with the exception of
the colour reaction at 37 °C.
Production of synthetic advanced glycation
endproducts
Bovine serum albumin or chicken egg albumin (50 g/1) were incu-
bated in 0.1 mol/1 phosphate buffer (pH 7.9) at 50 °C with 1 mol/1
glucose for 2 months in loosely capped bottles. Water was added
twice a week to compensate for solvent evaporation. Synthetic ad-
vanced glycation endproducts were dialysed extensively against
phosphate buffer to remove non-protein bound advanced glycation
endproducts and residual sugars.
Protein precipitation with trichloroacetic acid
Serum proteins of 21 patients were precipitated with trichloroacetic
acid 100 g/1 for 20 minutes on ice (17). After centrifugation for 15
minutes at 5000 g and 3 washing steps with trichloroacetic acid
100 g/1, the pellets were redissolved in 0.1 mol/1 Tris buffer (pH
11.3), then used for SDS polyacrylamide gel electrophoresis and
fluorescence spectroscopy.
Gel filtration chromatography
Molecular masses of serum advanced glycation endproducts (50
μΐ) were determined by gel filtration chromatography on a Toso-
haas TSKgel G 3000 SW column in phosphate-buffered saline.
Flow rate was set to 2 ml/min. Absorption was measured with a
Biorad 1706 UV/VIS photometer at 280 nm and with a Merck-
Hitachi F-1080 fluorospectrometer at a excitation wavelength of
370 nm and an emission wavelength of 440 nm. Bovine serum
albumin (MT 67 000), chicken egg albumin (Mr 46 000) and cyto-
chrome c (Mr 12000) were used as molecular mass standards for
calibration of the column.
Statistics
Statistical evaluation was performed with the Macintosh based
Abacus Statview program. Correlations were calculated using
Fischer's r to z with pairwise deletions. Statistical significance
among groups was calculated by Student's t test for unpaired sam-
ples.
Results
Validation of the method
Advanced glycation endproduct levels determined by
competitive ELISA have been shown to be robust
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towards different assay conditions such as sample prepa-
ration, delipidation or (compared with internal stan-
dards) different antibody batches (8, 9, 16).
In contrast, the characteristic advanced glycation end-
product fluorescence is more likely to be sensitive to
unspecific interferences, e.g. by low molecular mass
fluorescent compounds with similar emission spectra
such as NADH, pteridine derivatives or haemoglobin. In
particular, NADH and pteridine derivatives (folk acid,
biopterin, neopterin) have fluorescence spectra similar
to advanced glycation endproducts.
Reduced pyridine nucleotide
NADH has an emission maximum of 440 nm, but its
concentration in serum is negligible, except when mas-
sive cell lysis with release from intracellular compart-
ments occurs. However, there is no indication for an
increased NADH level in the plasma of dialysis pa-
tients.
Pteridine derivatives
This second class of low molecular mass fluorescent
compounds in serum consists of substances containing
the pteridine ring such as folic acid, biopterin and
neopterin. While the fluorescence of folic acid is neglig-
ible at physiological concentrations, biopterin and
neopterin may contribute up to 1% to the total fluores-
cence at maximum physiological levels (tab. 1).
Haemoglobin
Haemoglobin might also interfere with advanced glyca-
tion endproduct fluorescence emission. When haemo-
globin was added in increasing concentrations up to 0.1
g/1 to serum samples, the emission maximum gradually
shifted to 455 nm and the signal at the reference emis-
sion wavelength at 445 nm was reduced up to 8.5%,
presumably by quenching. At higher concentrations of
haemoglobin, the maximum emission peak shifted to
460 nm; clearly, therefore, haemolytic sera should not
be measured. However, the haemoglobin concentration
in all tested serum samples did not exceed the physio-
logical reference interval of 0.1 g/1 (18).
The serum level of the compounds mentioned above can
also be estimated by observing pH-dependent changes
in fluorescence. Whereas the fluorescence of advanced
glycation endproducts is insensitive to pH changes be-
tween pH 6 and 10, fluorescence emission of pteridine
derivatives as well as of NADH decreases at lower pH
values (tab. 1). Since fluorescence of the serum did not
change when the pH was lowered (tab. 1), it is likely
that these compounds do not significantly contribute to
the fluorescence of the serum.
Measurement of serum advanced glycation
endproduct level by competitive ELISAs
The competitive ELISA measures the ability of the se-
rum to compete with the immobilised advanced glyca-
tion endproduct on the microtitre plate surface for bind-
ing to the first advanced glycation endproduct antibody.
The serum samples were used in dilutions ranging from
1 : 16 to 1 : 2. The sample without added serum served
as internal standard on each plate and was defined as
B0. The degree of displacement of each dilution was
expressed as the B/B0 ratio. A serum dilution of 1 :4
yielded the best signal/noise ratio with a low standard
deviation, hence this dilution was used routinely and
should be regarded as the sensitivity limit of this assay.
To simplify data calculation, we have defined a 50%
competition (at a fixed serum dilution of 1 : 4) as 1 unit
of advanced glycation endproducts.
Polyclonal keyhole limpet haemocyanin advanced
glycation endproduct antibody
The polyclonal antibody was raised against an artificial
advanced glycation endproduct which had been pro-
duced by the incubation of keyhole limpet haemocyanin
Tab. 1 Fluorescence of possibly interfering compounds in the serum
Concentration
in serum
Concentration
measured
Fluorescence at
440 nm in 103 arb. units
pH 5.0a pH 7.6b
Biopterin
Folic acid
NADH
Haemoglobin
Advanced glycation endproduct-bovine serum albumin0
Serumd
< 35 nmol/1
5-20nmol/lc
0.1 g/le
100 nmol/1
100 nmol/1
100 nmol/1
0.1 g/1
0.1 g/1
125
0.8
0.45
39
400
460000
280
1.6
0.99
43
370
510000
a
 in 50 mmol/1 citrate buffer
b
 in phosphate-buffered saline
c
 artificial advanced glycation endproduct-bovine serum albumin
prepared by the incubation of bovine serum albumin 60 g/1 with
glucose 0.5 mol/1 at 50 °C for 2 months
d
 values for undiluted serum calculated from the values measured
at a dilution of 1 : 500
e
 from I.e. (20)
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Fig. 1 Displacement curves of the competitive ELISA using the
polyclonal keyhole limpet haemocyanin-advanced glycation end-
product antibody. A typical displacement curve of synthetic ad-
vanced glycation endproducts by serum samples of one control
(open circles) and three haemodialysis patients (triangles, filled
squares, filled circles) is shown in a dilution range from 1 :2 to
1 : 16. Assays were done in triplicate, B/B0 values are shown as
mean ± SD.
with glucose. It has been shown that Ne-(carboxymeth-
yl)lysine is the major antigenic epitope detected by this
common types of advanced glycation endproduct anti-
body (19, 20). Typical displacement curves for the poly-
clonal antibody (one control and 3 maintenance haemo-
dialysis patients) are shown in figure 1. When this anti-
body was used, the serum advanced glycation endpro-
duct level of the haemodialysis patients (0.32 ±0.16
units) were found to be significantly higher than that of
the control subjects (0 ± 0.26, ρ < 0.0001), but with a
significant overlap between the patient and control
group (fig. 2, tab. 2). No difference could be detected
between diabetic and non-diabetic dialysis patients (tab.
2). The calculated advanced glycation endproduct level
of around zero for the control subjects does not imply
that their serum is devoid of advanced glycation endpro-
ducts. This result is probably due to the set-up of the
assay. Bovine serum albumin, which is assumed to bind
the same number of advanced glycation endproduct epi-
topes as human serum albumin in the tested sera, is used
as a blocking reagent in the ELISA; it provides an ex-
cess of binding sites for the polyclonal antibody on the
microtitre plate surface which is then unavailable for
competition. The use of Tween 20 as an alternative
blocking reagent led to a slightly lower background, but
much higher standard errors among the triplicate mea-
surements.
Monoclonal imidazolone antibody
The monoclonal antibody was raised against imidazo-
lone, a reaction product of arginine and 3-deoxygluco-
sone, which was shown to be accumulated in the amy-
loid tissues of uraemic patients (3). The displacement
curves were very similar to those of the polyclonal anti-
body with a maximal displacement of 53% (1.06 units)
for the patient serum with the highest imidazolone level.
When this antibody was used, the advanced glycation
endproduct level of the haemodialysis patients (0.30
± 0.25 units) was also found to be significantly higher
than that of the control subjects (0.13 ± 0.12, ρ < 0.05),
with a significant overlap between the patient and con-
trol group (fig. 3, tab. 2). No significant difference could
be detected between diabetic and non-diabetic haemodi-
alysis patients (tab. 2).
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Fig. 2 Comparison of advanced glycation endproduct levels in
serum of haemodialysis patients and controls measured by compet-
itive ELISA (polyclonal keyhole limpet haemocyanin-advanced
glycation endproduct antibody). The advanced glycation endpro-
duct level in serum (at a 1 :4 dilution) is 0 ± 0.26 units in the
control group (left column) and 0.32 ± 0.16 units in the mainte-
nance haemodialysis patients group (right column); these values
are significantly different (p < 0.0001).
Tab. 2 Advanced glycation endproduct levels in diabetic and non-diabetic maintenance dialysis
patients determined by three independent assays
ELISA
(polyclonal advanced
glycation endproduct antibody)
[units]
ELISA
(monoclonal imidazolone
antibody)
[units]
Total fluorescence
[103 arb. units]
Control
Non-diabetic haemodialysis patients
Diabetic haemodialysis patients
0 + 0.26 (n = 20)
0.33 +0.17 (n = 120)
0.30 + 0.15(n = 37)
0.13 + 0.12(n= 12)
0.33 + 0.28 (n = 43)
0.23 + 0.17(n= 14)
30.4+ 6.1(n = 21)
113.4 + 27.1 (n = 116)
107.9 + 29.1 (n = 37)
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Fig. 3 Comparison of advanced glycation endproduct levels in
serum of haemodialysis patients and controls measured by compet-
itive ELISA (monoclonal imidazolone antibody). The advanced
glycation endproduct level in serum (at a 1:4 dilution) is 0.13
±0.12 units in the control group (left column) and (0.30 ± 0.25
units) in the haemodialysis patients group (right column); these
values are significantly different (p < 0.05).
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Fig. 4 Fluorescence spectra of synthetic advanced glycation end-
products and advanced glycation endproducts in serum. A fluores-
cence emission scan between 400 and 540 nm (excitation at 370
nm) was recorded with synthetic advanced glycation endproducts
and serum. All tested synthetic advanced glycation endproducts
(bovine serum albumin-advanced glycation endproduct is shown
as a representative sample) show a fluorescence spectrum nearly
identical to that of serum.
Measurement of serum advanced glycation
endproduct level by fluorescence spectroscopy
Protein-bound fluorescent substances in tissue and blood
are generated by a complex reaction cascade involving
glycation and oxidation ("glycoxidation") accompanied
by the formation of oxygen free radicals with subse-
quent lipid peroxidation and protein oxidation (21—23).
Although oxidised amino acids on proteins also contrib-
ute to serum fluorescence (24), a similar fluorescence
spectrum of synthetic advanced glycation endproducts
and of those of serum supports the assumption that ad-
vanced glycation endproducts are the main fluorescent
species in the serum of haemodialysis patients (fig. 4).
The advanced glycation endproduct level was de-
termined by quantitative fluorescence spectroscopy
with the same serum samples as used for the ELISAs.
As in the immunological assays, significantly elevated
advanced glycation endproduct levels were detectable
in maintenance haemodialysis patients compared with
the control subjects (111.9 X 103 ±27.6 Χ 103
vs. 30.7 X 103 ±6.2 Χ 103 arbitrary fluorescence
units, ρ < 0.0001). Interestingly, there was only a min-
imal overlap between the control and patient group
(fig. 5).
Determination of the molecular mass of
fluorescent advanced glycation endproducts
We used two methods, protein precipitation by tri-
chloroacetic acid and gel filtration chromatography, to
determine which structures the fluorescence is bound to.
Firstly, serum of 21 patients was precipitated with tri-
chloroacetic acid. Trichloroacetic acid precipitates pro-
teins and DNA, but leaves low molecular mass com-
pounds (e. g. low molecular mass peptides, oligonucleo-
tides and organic compounds) in the supernatant (17).
Analysis of the redissolved protein pellet by SDS poly-
acrylamide gel electrophoresis showed that predomi-
nantly albumin is recovered (data not shown). Fluores-
cence in the redissolved pellet decreased from 29.6
X 103 ± 4.8 X 103 to 20.7 X 103 ± 11.2 Χ 103 arbi-
trary units in the control (n = 12), and from 114.4 Χ 103
± 25.7 X 103 to 61.9 X 103 arbitrary units in the
haemodialysis patient group (n = 9). The fluorescence
after the trichloroacetic acid precipitation step correlated
well with the total fluorescence (r = 0.81, ρ < 0.0001),
indicating that the albumin advanced glycation endpro-
duct content reflects closely the total fluorescence in se-
rum.
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Fig. 5 Comparison of advanced glycation endproduct level in se-
rum of haemodialysis patients and controls measured by fluores-
cence spectroscopy. Fluorescence spectra (emission: 370 nm; exci-
tation: 445 nm) show a significant increase (p < 0.0001) in ad-
vanced glycation endproducts in maintenance haemodialysis pa-
tients (111.9 X 103 ± 27.6 Χ 103 arbitrary units, right column)
compared with the control subjects (30.7 X 103 ± 62. Χ 103 arbi-
trary units, left column).
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Secondly, the distribution of the molecular masses of
the substances responsible for the advanced glycation
endproduct specific fluorescence was determined in
more detail by gel filtration and fluorescence detection.
Fifty (50) μΐ of serum was separated on a TSKgel filtra-
tion column (separation range Mr 20000 to 200000).
Figure 6 shows a typical chromatogram of these serum
of a haemodialysis patient with normal albumin levels
prior to dialysis. Most of the fluorescence of the 10
haemodialysis patients tested co-eluted with the human
serum albumin peak (retention time: 28 min), with a
minor peak/shoulder around Mr 14000 (retention time:
41 min). However, the pattern of advanced glycation
endproducts distribution, particularly in the low molecu-
lar mass range, was quite different for each individual
patient, probably depending on dietary uptake, residual
kidney function, medication (e. g. antioxidants) and the
type of haemodialysis membrane used; this will be re-
ported elsewhere.
Comparison between ELISA and fluorescence
Comparison of the three assays showed significant dif-
ferences between the control and the haemodialysis pa-
tient group independent of the assay used; the largest
difference between the patient and control group was
seen in the total fluorescence (fig. 7). Significant corre-
lations of the total fluorescence with both the keyhole
limpet haemocyanin advanced glycation endproduct an-
tibody (r = 0.474, p < 0.001, n = 173) and the imidazo-
lone antibody (r = 0.396, p < 0.001, n = 69) were
found (fig. 8, 9). However, no correlation could be de-
tected between the two ELISAs (r = 0.164, p = 0.18,
n = 67). This difference between the two immunologi-
cal assays suggests a different distribution of advanced
glycation endproducts in each patient.
Discussion
Using competitive ELISAs with antibodies raised
against various model advanced glycation endproducts,
several groups have shown that plasma concentrations
of advanced glycation endproducts are slightly elevated
in diabetic patients with normal renal function and ex-
tremely elevated in both diabetic and non-diabetic pa-
tients with end-stage renal disease (7—9, 16). The most
noxious fraction is believed to consist of low molecular
mass advanced glycation endproducts which retain
strong cross-linking activity with matrix proteins in vi-
tro. Advanced glycation endproduct-peptides hi the hu-
man circulation may represent a hitherto unrecognised
class of reactive and potentially toxic substances which
can exacerbate renal and extrarenal vascular pathology
and render these patients sensitive to accelerated ath-
erosclerosis. Elimination of these circulating low mo-
lecular mass advanced glycation endproducts by the
kidney is impaired in patients with end-stage renal
disease and this function is inadequately performed by
the current types of dialysis membranes (6, 25). Hence
a rapid and sensitive assay for the determination of
advanced glycation endproducts in serum might be
valuable for assessing cardiovascular risks and for
monitoring the efficacy of advanced glycation endpro-
duct removal procedures (by dialysis or adsorption),
or for testing novel pharmacological approaches for
inhibition of their formation.
Significantly elevated advanced glycation endproducts
levels in the sera of haemodialysis patients compared
with the controls were detected with each of the three
advanced glycation endproduct assays. However, there
was no difference between diabetic and non-diabetic pa-
tients, suggesting that increased advanced glycation end-
product formation from precursors or the insufficient
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Fig. 6 Analysis of serum proteins of haemodialysis patients by
gel filtration chromatography. The molecular mass distribution of
the substances with advanced glycation endproduct-specific fluo-
rescence was determined by gel filtration on a Tosohaas TSKgel G
3000 SW gel filtration column and UV/Vis and fluorescence detec-
tion (absorption: 280 nm, open circles; fluorescence: excitation:
370 nm/emission 440 nm, triangles).
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Fig. 7 Comparison between advanced glycation endproduct de-
terminations by ELISAs and fluorescence spectroscopy. Compari-
son of the three assays showed significant differences between the
control and the haemodialysis patient group by advanced glycation
endproduct-ELISA (A), Imidazolone-.ELISA (B), total fluores-
cence (C) and fluorescence of the protein pellet after trichloroacetic
acid precipitation (D).
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Fig. 8 Correlation of advanced glycation endproduct-ELISA with
total serum fluorescence. Comparison of both assays showed a sig-
nificant correlation of advanced glycation endproduct level (deter-
mined by competitive ELISA with the polyclonal keyhole limpet
haemocyanin-advanced glycation endproduct antibody) and total
serum fluorescence (correlation coefficient r = 0.474; p < 0.001).
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Fig. 9 Correlation of imidazolone-ELISA with total serum fluo-
rescence. Comparison of both assays showed a significant correla-
tion of imidazolone level (determined by competitive ELISA with
the monoclonal imidazolone antibody) and total serum fluores-
cence (correlation coefficient r = 0.396; p < 0.001).
clearance of advanced glycation endproducts during di-
alysis is more important than glycation.
Advanced glycation endproduct measurement by ELISA
is quite specific, since the antibodies are specifically
raised against advanced glycation endproduct-proteins
or synthetic model advanced glycation endproducts.
However, among the probably hundreds of different pro-
tein-bound types of advanced glycation endproducts,
only a few have been chemically defined, thereby en-
abling their use as antigens for the production of specific
antibodies; these include carboxymethyllysine, imidazo-
lone, pentosidine and pyrraline (26—28). Antibodies
used in ELISAs for advanced glycation endproduct can
range from very specific monoclonal antibodies against
synthetic compounds such as imidazolone to general
polyclonal antibodies against an advanced glycation
endproduct modified protein such as keyhole limpet
haemocyanin. Further disadvantages of the immunologi-
cal assays are the low sensitivity (detection limit: 75 μΐ
serum for a triplicate determination) as well as the long
analysis time which limits their use for advanced glyca-
tion endproduct measurement during dialysis (tab. 3).
As long as the pathophysiological relevance of a certain
advanced glycation endproduct's structure is not known,
it is difficult to select one particular advanced glycation
endproduct as the antigen for an immunological assay.
Total fluorescence of serum measures a combination of
mainly protein-bound glycoxidation and oxidation pro-
ducts. Among the many fluorescent advanced glycation
endproducts, only a few have been identified so far. Pen-
tosidine is a fluorescent condensation product of lysine,
arginine and ribose. However, its emission maximum at
395 nm (excitation: 335 nm) is not characteristic for
native advanced glycation endproducts, suggesting that
this is only a minor product (29). A second class of
fluorescent compounds, the crosslinks, were shown to
be one of the major fluorescent advanced glycation end-
products produced in a reaction mixture of free amino
groups such as lysine with glucose in vitro, with fluores-
cent spectra similar to those of advanced glycation end-
product proteins (30). Our data show that total fluores-
cence is mainly associated with high molecular mass
proteins, particularly albumin. This is supported by
Monnier et al., who showed that 90% of pentosidine of
Tab. 3 Comparison of advanced glycation endproduct assays in terms of sample size, time
requirements and inter-assay variations
ELISA ELISA
(advanced glycation endproduct) (imidazolone)
Sample size (triplicate)
Analysis time
Inter-assay variation
75 μΐ
>4h
6.60%
75 μΐ
>4h
5.54%
Fluorescence spectroscopy
20 μΐ
< 10min
8.9%
(triplicates on the same day)
8.75%
(day to day variation, 3 days)
(triplicates on the same day)
4.35%
(day to day variation, 3 days)
(triplicates on the same day)
10.5%
(day to day variation, 5 days)
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plasma proteins from end-stage renal disease patients is
linked to high molecular mass proteins and only 1 —2%
is in free form (31).
The correlation of total fluorescence with advanced gly-
cation endproduct level measured by ELISA indicates
that the chemical reactions leading to the generation of
fluorescence and both antigenic epitopes are related,
probably involving an oxidation step of the glycated pro-
tein. The non-significant correlation between the two
ELISAs, however, shows that both antigenic structures
are unequally distributed in the maintenance haemodia-
lysis patients. This difference between the two immuno-
logical assays suggests a distinct distribution of ad-
vanced glycation endproducts for each patient.
The relevance and specificity of total fluorescence is
still controversial. As demonstrated by us and other
authors, low molecular mass fluorescent advanced gly-
cation endproducts, e.g. derived from nutrition, are
only a minor problem since the main fluorescent spe-
cies are protein-bound compounds (31). Although the
fluorescent compounds contained in lipofuscin, ceroid,
advanced glycation endproducts, and age pigment-like
fluorophores can be produced from different types of
biological materials by side reactions during essential
biological processes, the crosslinking of carbonyl-
amino compounds is recognised as a common process
during their formation (32).
Formation of advanced glycation endproducts and pro-
tein oxidation are closely linked. In particular, glycated
proteins produce Superoxide radicals which lead to a
site-specific oxidation of adjacent proteins (33). In addi-
tion, not only protein-bound ^wai/on'-products, but also
on amino acids are subject to transition metal-catalysed
oxidation, leading to the formation of advanced oxida-
tion protein products. Their levels have been shown to
correlate with plasma concentrations of dityrosine and ad-
vanced glycation endproduct-pentosidine, as indices of
oxidant-mediated protein damage, but not with thiobarbi-
turic acid reactive substances which serve as lipid peroxi-
dation markers. In a further study, the level of pentosidine,
a marker of glycation, and the intensity of collagen-linked
fluorescence glycation (370/440 and 335/385 nm), and
oxidation-related (356/460 and 390/460 nm) and glycated
haemoglobin showed a good correlation (34).
However, for the rapid monitoring of the removal of low
molecular mass serum advanced glycation endproducts
from dialysis patients, the precise origin of the fluores-
cent substances might be of secondary importance. They
might rather serve as representative markers for the effi-
cacy of dialysis.
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